Literature DB >> 11045979

Altered hemodynamics in transgenic mice harboring mutant tropomyosin linked to hypertrophic cardiomyopathy.

C C Evans1, J R Pena, R M Phillips, M Muthuchamy, D F Wieczorek, R J Solaro, B M Wolska.   

Abstract

We used transgenic (TG) mice overexpressing mutant alpha-tropomyosin [alpha-Tm(Asp175Asn)], linked to familial hypertrophic cardiomyopathy (FHC), to test the hypothesis that this mutation impairs cardiac function by altering the sensitivity of myofilaments to Ca(2+). Left ventricular (LV) pressure was measured in anesthetized nontransgenic (NTG) and TG mice. In control conditions, LV relaxation was 6,970 +/- 297 mmHg/s in NTG and 5,624 +/- 392 mmHg/s in TG mice (P < 0.05). During beta-adrenergic stimulation, the rate of relaxation increased to 8,411 +/- 323 mmHg/s in NTG and to 6,080 +/- 413 mmHg/s in TG mice (P < 0.05). We measured the pCa-force relationship (pCa = -log [Ca(2+)]) in skinned fiber bundles from LV papillary muscles of NTG and TG hearts. In control conditions, the Ca(2+) concentration producing 50% maximal force (pCa(50)) was 5.77 +/- 0.02 in NTG and 5.84 +/- 0.01 in TG myofilament bundles (P < 0.05). After protein kinase A-dependent phosphorylation, the pCa(50) was 5.71 +/- 0.01 in NTG and 5.77 +/- 0. 02 in TG myofilament bundles (P < 0.05). Our results indicate that mutant alpha-Tm(Asp175Asn) increases myofilament Ca(2+)-sensitivity, which results in decreased relaxation rate and blunted response to beta-adrenergic stimulation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11045979     DOI: 10.1152/ajpheart.2000.279.5.H2414

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  23 in total

Review 1.  Vertebrate tropomyosin: distribution, properties and function.

Authors:  S V Perry
Journal:  J Muscle Res Cell Motil       Date:  2001       Impact factor: 2.698

2.  Myocardial infarction in mice alters sarcomeric function via post-translational protein modification.

Authors:  Benjamin S Avner; Krystyna M Shioura; Sarah B Scruggs; Milana Grachoff; David L Geenen; Donald L Helseth; Mariam Farjah; Paul H Goldspink; R John Solaro
Journal:  Mol Cell Biochem       Date:  2011-12-08       Impact factor: 3.396

3.  Effects of the mutation R145G in human cardiac troponin I on the kinetics of the contraction-relaxation cycle in isolated cardiac myofibrils.

Authors:  M Kruger; S Zittrich; C Redwood; N Blaudeck; J James; J Robbins; G Pfitzer; R Stehle
Journal:  J Physiol       Date:  2005-02-17       Impact factor: 5.182

4.  Functional effects of a tropomyosin mutation linked to FHC contribute to maladaptation during acidosis.

Authors:  Katherine A Sheehan; Grace M Arteaga; Aaron C Hinken; Fernando A Dias; Cibele Ribeiro; David F Wieczorek; R John Solaro; Beata M Wolska
Journal:  J Mol Cell Cardiol       Date:  2010-11-01       Impact factor: 5.000

Review 5.  Sarcomeric proteins and familial hypertrophic cardiomyopathy: linking mutations in structural proteins to complex cardiovascular phenotypes.

Authors:  Jil C Tardiff
Journal:  Heart Fail Rev       Date:  2005-09       Impact factor: 4.214

6.  Enhanced active cross-bridges during diastole: molecular pathogenesis of tropomyosin's HCM mutations.

Authors:  Fan Bai; Adam Weis; Aya K Takeda; P Bryant Chase; Masataka Kawai
Journal:  Biophys J       Date:  2011-02-16       Impact factor: 4.033

7.  Chronic Calmodulin-Kinase II Activation Drives Disease Progression in Mutation-Specific Hypertrophic Cardiomyopathy.

Authors:  Sarah J Lehman; Lauren Tal-Grinspan; Melissa L Lynn; Joshua Strom; Grace E Benitez; Mark E Anderson; Jil C Tardiff
Journal:  Circulation       Date:  2019-03-19       Impact factor: 29.690

8.  Differential effect of troponin T mutations on the inotropic responsiveness of mouse hearts--role of myofilament Ca2+ sensitivity increase.

Authors:  Syevda G Sirenko; James D Potter; Björn C Knollmann
Journal:  J Physiol       Date:  2006-06-15       Impact factor: 5.182

9.  Desensitization of myofilaments to Ca2+ as a therapeutic target for hypertrophic cardiomyopathy with mutations in thin filament proteins.

Authors:  Marco L Alves; Fernando A L Dias; Robert D Gaffin; Jillian N Simon; Eric M Montminy; Brandon J Biesiadecki; Aaron C Hinken; Chad M Warren; Megan S Utter; Robert T Davis; Sadayappan Sakthivel; Jeffrey Robbins; David F Wieczorek; R John Solaro; Beata M Wolska
Journal:  Circ Cardiovasc Genet       Date:  2014-02-28

Review 10.  Investigations into tropomyosin function using mouse models.

Authors:  Ganapathy Jagatheesan; Sudarsan Rajan; David F Wieczorek
Journal:  J Mol Cell Cardiol       Date:  2009-10-14       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.